High incidence of anticytomegalovirus drug resistance among D+R-kidney transplant recipients receiving preemptive therapy

American Journal of Transplantation

Volumn 12, Issue 1, 2012, Pages 202-209

  Couzi, L ^a,b,c   Helou, S ^a,c   Bachelet, T ^a,c   Moreau, K ^a   Martin, S ^a   Morel, D ^a   Lafon, M E ^a,c,d   Boyer, B ^e   Alain, S ^e   Garrigue, I ^a,c,d   Merville, P ^a,b,c  

^a HÔPITAL PELLEGRIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d University Victor Segalen   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Antiviral resistance; cytomegalovirus (CMV); kidney transplantation; mutation; preemptive therapy; prophylaxis

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG TREATMENT FAILURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; VIRUS LOAD;

CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION;

EID: 84855959376     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03766.x     Document Type: Article

References (33)

1. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89 779-795.
2. Drew WL, Paya CV, Emery V,. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 2001; 1 307-312. (Pubitemid 33681692)
3. Lurain NS, Chou S,. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 689-712.
4. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR,. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22 162-170. (Pubitemid 351420009)
5. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP,. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45 439-447. (Pubitemid 47204459)
6. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M,. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 645-649. (Pubitemid 30627592)
7. Limaye AP,. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35 866-872.
8. Emery VC, Griffiths PD,. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97 8039-8044. (Pubitemid 30460769)
9. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M,. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 20-27. (Pubitemid 34043012)
10. Humar A, Michaels M,. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 262-274. (Pubitemid 43382161)
11. Asberg A, Humar A, Rollag H, et al,. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 2106-2113. (Pubitemid 47247057)
12. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM,. Expanded criteria donors for kidney transplantation. Am J Transplant 2003; 3 114-125. (Pubitemid 36612389)
13. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8 753-760. (Pubitemid 351347767)
14. Garrigue I, Doussau A, Asselineau J, et al,. Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol 2008; 46 493-498. (Pubitemid 351231292)
15. Chou S, Marousek G, Boivin G, et al,. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010; 90 1409-1413.
16. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al,. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2010; 65 2628-2640.
17. Khoury JA, Storch GA, Bohl DL, et al,. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6 2134-2143. (Pubitemid 44199547)
18. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F,. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8 975-983. (Pubitemid 351537752)
19. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V,. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8 69-77.
20. Singh N,. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006; 16 281-287. (Pubitemid 44497309)
21. Sun HY, Wagener MM, Singh N,. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008; 8 2111-2118.
22. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 1228-1237.
23. Boivin G, Goyette N, Rollag H, et al,. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14 697-704.
24. Boutolleau D, Deback C, Bressollette-Bodin C, et al,. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81 174-179.
25. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD,. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190 177-182. (Pubitemid 29354911)
26. Humar A, Kumar D, Preiksaitis J, et al,. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5 1462-1468. (Pubitemid 40839439)
27. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 611-620. (Pubitemid 38523584)
28. Asberg A, Humar A, Jardine AG, et al,. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 1205-1213.
29. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al,. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191 89-92. (Pubitemid 40041405)
30. Asberg A, Jardine AG, Bignamini AA, et al,. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010; 10 1881-1888.
31. van der Beek MT, Berger SP, Vossen AC, et al,. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance. Transplantation 2010; 89 320-326.
32. Bhorade SM, Lurain NS, Jordan A, et al,. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21 1274-1282. (Pubitemid 35477741)
33. Isada CM, Yen-Lieberman B, Lurain NS, et al,. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transplant Infect Dis 2002; 4 189-194. (Pubitemid 36142804)